Results 1 to 10 of about 749,470 (229)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma [PDF]

Molecular Oncology, 2020
Detection of amplification of the MYCN gene is essential for determining optimal treatment and estimating prognosis of patients with neuroblastoma (NB).
Yan Su, Lijun Wang, Qian Zhao, Zhixia Yue, Wen Zhao, Xisi Wang, Chao Duan, Mei Jin, Dawei Zhang, Shenglan Chen, Jianfeng Yin, Lihua Qiu, Xianfeng Cheng, Zhong Xu, Xiaoli Ma   +14 more
doaj   +6 more sources

Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification [PDF]

Cancer Communications, 2019
Background Interphase fluorescence in situ hybridization (FISH) of bone marrow cells has been confirmed to be a direct and valid method to assess the v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) amplification in ...
Zhi-Xia Yue, Tian-Yu Xing, Chao Gao, Shu-Guang Liu, Wen Zhao, Qian Zhao, Xi-Si Wang, Mei Jin, Xiao-Li Ma   +8 more
doaj   +5 more sources

Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples [PDF]

BMC Cancer, 2019
Background MYCN amplification directly correlates with the clinical course of neuroblastoma and poor patient survival, and serves as the most critical negative prognostic marker.
Dinesh Babu Somasundaram, Sheeja Aravindan, Zhongxin Yu, Muralidharan Jayaraman, Ngoc T. B. Tran, Shibo Li, Terence S. Herman, Natarajan Aravindan   +7 more
doaj   +4 more sources

An integrative radiological, histopathological and molecular analysis of pediatric pontine histone-wildtype glioma with MYCN amplification (HGG-MYCN). [PDF]

Acta Neuropathol Commun, 2019
The 2016 WHO Classification of tumours of the central nervous system has introduced a new histomolecular entity, the midline diffuse glioma, H3K27M-mutant [8].
Tauziède-Espariat A, Debily MA, Castel D, Grill J, Puget S, Sabel M, Blomgren K, Gareton A, Dangouloff-Ros V, Lechapt E, Boddaert N, Varlet P.   +11 more
europepmc   +10 more sources

MYCN amplification and ATRX mutations are incompatible in neuroblastoma. [PDF]

Nat Commun, 2020
Aggressive cancers often have activating mutations in growth-controlling oncogenes and inactivating mutations in tumor-suppressor genes. In neuroblastoma, amplification of the MYCN oncogene and inactivation of the ATRX tumor-suppressor gene correlate ...
Zeineldin M, Federico S, Chen X, Fan Y, Xu B, Stewart E, Zhou X, Jeon J, Griffiths L, Nguyen R, Norrie J, Easton J, Mulder H, Yergeau D, Liu Y, Wu J, Van Ryn C, Naranjo A, Hogarty MD, Kamiński MM, Valentine M, Pruett-Miller SM, Pappo A, Zhang J, Clay MR, Bahrami A, Vogel P, Lee S, Shelat A, Sarthy JF, Meers MP, George RE, Mardis ER, Wilson RK, Henikoff S, Downing JR, Dyer MA.   +36 more
europepmc   +10 more sources

MYCN amplification drives an aggressive form of spinal ependymoma. [PDF]

Acta Neuropathol, 2019
Spinal ependymal tumors form a histologically and molecularly heterogeneous group of tumors with generally good prognosis. However, their treatment can be challenging if infiltration of the spinal cord or dissemination throughout the central nervous ...
Ghasemi DR, Sill M, Okonechnikov K, Korshunov A, Yip S, Schutz PW, Scheie D, Kruse A, Harter PN, Kastelan M, Wagner M, Hartmann C, Benzel J, Maass KK, Khasraw M, Sträter R, Thomas C, Paulus W, Kratz CP, Witt H, Kawauchi D, Herold-Mende C, Sahm F, Brandner S, Kool M, Jones DTW, von Deimling A, Pfister SM, Reuss DE, Pajtler KW.   +29 more
europepmc   +8 more sources

High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma [PDF]

Acta Neuropathologica Communications, 2020
We report a novel group of clinically aggressive spinal cord ependymomas characterized by Grade III histology, MYCN amplification, an absence of NF2 alterations or other recurrent pathogenic mutations, and a unique methylation classifier profile.
Mark Raffeld, Zied Abdullaev, Svetlana D. Pack, Liqiang Xi, Sushma Nagaraj, Nicole Briceno, Elizabeth Vera, Stefania Pittaluga, Osorio Lopes Abath Neto, Martha Quezado, Kenneth Aldape, Terri S. Armstrong, Mark R. Gilbert   +12 more
doaj   +3 more sources

Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. [PDF]

Pediatr Blood Cancer, 2019
MYCN amplification (MYCN‐A) is an established adverse prognostic factor in neuroblastoma. The extent to which the prognostic impact of MYCN‐A depends on other factors has not been fully characterized.
Campbell K, Shyr D, Bagatell R, Fischer M, Nakagawara A, Nieto AC, Brodeur GM, Matthay KK, London WB, DuBois SG.   +9 more
europepmc   +4 more sources

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study. [PDF]

Br J Cancer, 2018
In neuroblastoma (NB), the most powerful prognostic marker, the MYCN amplification (MNA), occasionally shows intratumoural heterogeneity (ITH), i.e. coexistence of MYCN-amplified and non-MYCN-amplified tumour cell clones, called heterogeneous MNA (hetMNA)
Berbegall AP, Bogen D, Pötschger U, Beiske K, Bown N, Combaret V, Defferrari R, Jeison M, Mazzocco K, Varesio L, Vicha A, Ash S, Castel V, Coze C, Ladenstein R, Owens C, Papadakis V, Ruud E, Amann G, Sementa AR, Navarro S, Ambros PF, Noguera R, Ambros IM.   +23 more
europepmc   +10 more sources

CD133 expression and amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma [PDF]

Journal of International Medical Research, 2018
Objectives Neuroblastoma (NB) is the most common pediatric solid tumor derived from the sympathetic nervous system. MYCN is amplified in nearly half of patients with NB, and its association with rapid disease progression and poor outcome is controversial.
Zhi-Yong Zhong, Bao-Jun Shi, Hui Zhou, Wen-Bo Wang   +3 more
doaj   +3 more sources